Stock OCUL OCULAR THERAPEUTIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Real-time Estimate Cboe BZX
Other stock markets
 11:58:14 2024-04-26 am EDT 		5-day change 1st Jan Change
4.195 USD -0.12% Intraday chart for Ocular Therapeutix, Inc. -20.98% -7.51%
Apr. 18 Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
Apr. 18 Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy
AQ
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup
DJ
Ocular Therapeutix : Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K
PU
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall
MT
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
AQ
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy
CI
Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
AQ
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
AQ
Ocular Therapeutix CEO Antony Mattessich Steps Down; Pravin Dugel Named Successor
MT
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
AQ
Ocular Therapeutix, Inc. Announces Executive Changes
CI
Ocular Therapeutix, Inc. Announces CEO Changes
CI
Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4) to Senior Vice President of Global Head of Biometrics
AQ
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
AQ
Ocular Therapeutix Announces Positive Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
AQ
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
AQ
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
CI
Ocular Therapeutix to Present Data at the 2024 ASCRS Annual Meeting
AQ
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
AQ
Ocular Therapeutix Files Shelf for Common Stock Sale by Stockholders; Shares Fall After Hours
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCUL Stock
  4. News Ocular Therapeutix, Inc.